Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Robert F. Kennedy Jr., Trump's pick to head the Department of Health and Human Services, faces scrutiny for fees he may earn ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Merck shares tumbled after the drugmaker said it was halting shipments of a top-selling vaccine to China to ...

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.

The pause announcement comes a month after Merck received approval in China for use of the vaccine in males. “We believe China still represents a significant, long-term opportunity for Gardasil ...

Shares of Merck slid Tuesday after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales forecast due partly to a pause in shipments of one of its top-selling products to China.